Cell Free DNA as a marker of inotrope related myocardial necrosis in heart failure

Not Applicable

• Conditions: Heart Failure; myocardial necrosis; Inotropes; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12622001153707
• Lead Sponsor: Heart and Lung Research Institute WA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-08-23
• Last Update Posted: 29 August 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Inpatients with FSH Advanced heart failure unit
- Consented to study participation
- Over 18 years of age
-Requiring IV administration of either
Noradrenaline
Dobutamine
Milrinone
Levosimendan
Adrenaline
Isoprenaline

Exclusion Criteria

oIntubated at time of inotrope commencement
-Post heart transplantation
- <48 hrs post PCI or device placement
- < 48 hrs post sustained VT or sustained atrial arrhythmias or any arrhythmias requiring
DCCV
- Recent MI

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Change in cardiac specific cfDNA between baseline and post inotrope commencement levels<br><br>[Blood sample times<br>1.. Decision to start inotrope<br>2. 3 hours post inotrope start<br>3. 24 hours post inotrope commencement<br>4. 24hrs post inotropes ceased.]

Secondary Outcome Measures

Name	Time	Method
evel of cfDNA in the blood measured against type and dose of inotrope<br><br><br><br>[-Before inotropes initiated, <br>-3 hours after inotropes initiated, <br>-24 hours after inotropes initiated <br>-24 hours post inotrope cessation. ]